Unfavorable survival in non-small cell lung cancer (NSCLC) may be related to high-expressed CD200R1, whereas CD200R1 knockdown could inhibit the cancer cell proliferation (Yoshimura et al., 2020). Here, CD200R1 is linked to non-small cell lung carcinoma.